The offering is a dilutive capital raise by a pre-revenue biotech with a going-concern warning. The stock closed at $9.35, below the $9.00 per-share equivalent offering price, suggesting weak demand. Monitor for further dilution risk from the warrant reset provision and any subsequent capital needs.
Price Chart
Executive Summary
EXOZYMES INC. is raising approximately $4.7 million (before expenses) through a registered direct offering of 592,270 shares of common stock and 296,135 warrants, priced at $18.00 per unit (two shares + one warrant). The offering is dilutive (7% of shares outstanding) and the company explicitly warns it may not be able to continue as a going concern, with only $1.44M cash and a $23.5M accumulated deficit as of March 31, 2026. The underwriter MDB Capital has a conflict of interest as its parent owns 46.1% of EXOZ.
Key Facts
- Offering of 592,270 shares (592,270 common + 296,135 warrants) at $18.00/unit, raising ~$4.7M net proceeds.
- Pro forma shares outstanding increase from 8,518,251 to 9,110,521 (~7% dilution).
- Net tangible book value per share is $0.18 pre-offering; new investors face $8.31 dilution per share.
- Cash and cash equivalents as of March 31, 2026: $1,444,562; accumulated deficit: $23,474,939.
- Company states it may not be able to continue as a going concern.
- Warrants have an exercise price reset to $0.001 if the company sells stock below the offering price within one year.
- Underwriter MDB Capital is a subsidiary of MDB Capital Holdings, which owns 46.1% of EXOZ pre-offering; FINRA conflict of interest declared.
- Stock closed at $9.35 on June 5, 2026, below the $9.00 per-share equivalent offering price.
Financial Impact
Dilution of ~7% of outstanding shares; net proceeds of ~$4.7M provide only short-term runway given $1.44M cash and ongoing losses.
Risk Factors
- Going-concern risk: company may not have sufficient liquidity to continue operations.
- Dilution from this offering and potential future offerings; warrant reset could cause massive dilution.
- No revenue; pre-commercialization stage with uncertain NCT product timeline.
- Conflict of interest with underwriter MDB Capital (parent owns 46.1%).
- Stock price already below offering price, indicating weak market reception.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-027611 |
| Document: 0001493152-26-027611-index-headers.html | 0001493152-26-027611 |
| Document: 0001493152-26-027611-index.html | 0001493152-26-027611 |
| Document: 0001493152-26-027611.txt | 0001493152-26-027611 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $5.25 | awaiting T+20 | — | $3.80 (−27.62%) |
Sep 28, 2026 29d ago | DEFA14A | $6.10 $3.80 | ▼ −37.70% | ▼ −38.42% | $3.80 (−37.70%) |
Sep 28, 2026 29d ago | DEF 14A | $6.10 $3.80 | ▼ −37.70% | ▼ −38.42% | $3.80 (−37.70%) |
Sep 18, 2026 5w ago | 8-K | $6.44 $4.09 | ▼ −36.44% | ▼ −36.65% | $3.80 (−40.95%) |
Jun 30, 2026 17w ago | 424B5 | $8.50 $4.40 | ▲ +48.24% | ▲ +46.05% | $3.80 (+55.29%) |
Jun 25, 2026 17w ago | 8-K | $8.03 $4.70 | ▼ −41.47% | ▼ −42.73% | $3.80 (−52.68%) |
Jun 17, 2026 18w ago | 8-K | $7.83 $6.22 | ▲ +20.56% | ▲ +21.09% | $3.80 (+51.47%) |
Jun 8, 2026 20w ago | 8-K | $8.62 $8.14 | ▲ +5.57% | ▲ +7.20% | $3.80 (+55.92%) |
Jun 8, 2026 20w ago | 424B5 | $8.62 $8.14 | ▲ +5.57% | ▲ +7.20% | $3.80 (+55.92%) |
Jun 4, 2026 20w ago | 424B5 | $9.35 $8.48 | ▲ +9.30% | ▲ +7.93% | $3.80 (+59.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers